In the survival analysis, we found that patients who had CD4+ and CD8+ T cells or their PD-1− subsets located nearer to tumor cells at baseline experienced worse OS and PFS (Figure 4F, Additional File: Figure S5). This evidence concerns the gene CD4 and neoplasm.